Rhamnolipid compounds and use thereof
US11286273B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 2019 |
| Grant date | Mar 29, 2022 |
| Priority date | — |
| Expiry date | Mar 8, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H1/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are a novel rhamnolipid compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof in the present disclosure. The novel rhamnolipid compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof selectively exhibits cytotoxicity to human cancer cell lines, thereby inhibiting the growth of cancer cells, and thus has particularly excellent preventive or therapeutic effects against the above-mentioned types of cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.